

Clinical Toxicology



ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ictx20

Severe Heloderma spp. envenomation: a review of the literature

Jean-Philippe Chippaux & Karim Amri

To cite this article: Jean-Philippe Chippaux & Karim Amri (2020): Severe Heloderma spp. envenomation: a review of the literature, Clinical Toxicology, DOI: 10.1080/15563650.2020.1853145

To link to this article: https://doi.org/10.1080/15563650.2020.1853145



Published online: 02 Dec 2020.



Submit your article to this journal 🕝



View related articles



View Crossmark data 🗹

REVIEW

() Check for updates

Tavlor & Francis

Taylor & Francis Group

Severe Heloderma spp. envenomation: a review of the literature

Jean-Philippe Chippaux^{a,b} D and Karim Amri^c

^aCRT, Institut Pasteur, Paris, France; ^bMERIT, IRD, Université Paris 5, Sorbonne Paris Cité, Paris, France; ^cSnakebite institute of Latin America, Belize, USA

ABSTRACT

Context: *Heloderma* bites are rare and generally mild, but a few cases can be life threatening. Methods: Description of *Heloderma* bite was searched in medical literature.

Discussion: We present a synthesis of clinical and biomedical effects of envenomation by *Heloderma* sp. based on 22 well identified cases described in medical literature. Three life-threatening syndromes, concomitant or not, may be involved: (a) angioedema which can lead to respiratory tract obstruction, (b) significant fluid losses due to diarrhea, vomiting and sweating, associated with hypokalemia and sometimes metabolic acidosis, and (c) atrioventricular conduction disorders simulating cardiac ischemia.

Conclusion: *Heloderma* bite are quite rare and generally mild. However, few severe cases may require emergency resuscitation. There is no antivenom, and the treatment is only symptomatic and supportive.

ARTICLE HISTORY

Received 24 September 2020 Revised 22 October 2020 Accepted 13 November 2020

KEYWORDS

Venomous lizard; envenomation; Heloderma suspectum; management

Introduction

Endemic to the southern United States, Mexico and northern Guatemala, the Helodermatidae family includes a single genus, *Heloderma* and five species *H. horridum* (Mexican beaded lizard), *H. suspectum* (Gila monster) and 3 species recently elevated from *H. horridum* subspecies: *H. alvarezii*, *H. charlesbogerti* and *H. exasperatum* [1,2]. It is the only group of lizards with specialized venomous glands situated in the lower jaw (Figure 1). The venom discharges through ducts ending close to grooved teeth that enable its inoculation. Devoid of muscle allowing expulsion of the venom, the latter penetrates into the bite by capillarity, greatly facilitated by the chewing action during the bite [3].

Heloderma do not use their venom to immobilize, kill and digest prey as most venomous animals do. Probably, the venom is primarily used as a defensive weapon [4], which is consistent with its remarkable genetic conservation despite an ancient separation of the *Heloderma* species (\sim 30 Ma), as well as the composition and properties of the venoms from *Heloderma* species [5,6]. The venom contains about 50 distinct proteins, including kallikrein-like serine proteinases, phospholipase A₂, bioactive amines, and low molecular weight toxins [6–8].

Heloderma bite envenomation cases appear to be relatively rare although several authors believe that they could be underreported [9]. However, in addition to the trauma from the bite, envenomation can be severe and even lifethreatening. A recent case of envenomation showing all the severe syndromes described after *Heloderma* bites [10], prompted us to look for similar cases in the literature. We compared the envenomations reported since the beginning of the twentieth Century to explain the pathogenesis of symptoms and to propose an appropriate management.

Methods

We searched PubMed and Google Scholar for medical and scientific publications using the words "*Heloderma*" and "*Heloderma* and bite", respectively, resulting in approximately 1200 references. We extracted 68 of them regarding *Heloderma* bite envenomation, venom composition, and pharmacology and experimental studies carried out with the venom. Then, we searched among the references cited in these publications, unreferenced documents that we obtained. Finally, we selected 43 articles for this study on the basis of their originality and relevant methodology or description.

Results and discussion

Most often, *H. suspectum* bites occur during capture or care of a captive specimen [7,11] while bites of *Heloderma horridum* sp. result either from an accident or from handling the animal. Bites are inflicted in the upper limb in more than 85% of the cases, in particular in the finger or hand (>80%). From a series of 105 *H. suspectum* bites in human, of which 79% were men, two-thirds of the victims were treated in health facility. Of these 71 patients seen in a health care facility, 17 (24%) were admitted. Eleven of these 17 admitted patients were in the ICU. Six had airway edema with two undergoing endotracheal intubation and one undergoing

CONTACT Jean-Philippe Chippaux 🖾 jean-philippe.chippaux@ird.fr 🗊 CRT, Institut Pasteur, 28 rue du Dr. Roux, 75015, Paris, France © 2020 Informa UK Limited, trading as Taylor & Francis Group



Figure 1. Heloderma suspectum cinctum Bogert & Martín Del Campo 1956 (Photo K. Amri).

cricothyrotomy after unsuccessful attempts at endotracheal intubation. These authors reported no death occurred in USA during a 12-year surveillance. Thirty deaths were mentioned until the 1940s [1,12], of which only 1 was confirmed and documented [13]. However, no deaths following *Heloderma* bite have been reported in the past 60 years.

We collected in the literature twenty-two documented Heloderma bites that are summarized in Table 1. Pain is constant and accompanied by regional ecchymotic edema of variable severity. Although the trauma of the bite can be significant, local lesions are usually moderate. Stahnke et al. [17] described hypoxic aspect of the bitten finger which they had attributed to a local arterial spasm; however, the patient had been treated before with local cryotherapy which may explain the spasm [18]. In another patient bitten in the hypothenar eminence, the radial pulse was impalpable while the Doppler showed normal arterial flow and venous return [18,19]. In most cases, general signs (diaphoresis, dizziness, nausea, vomiting) occur 5–15 min after the bite.

Biologically, the hemogram is little disturbed apart from neutrophilia [10,18,21,27]. Coagulation disorders are unusual and without clinically significant manifestations [20,23,24]. Hypokalemia can be clinically significant ($<3 \text{ mmol} \cdot \text{L}^{-1}$), generally asymptomatic, and associated with a moderate decrease in other blood electrolytes (phosphate, calcium, magnesium) [10,21,23,24]. Two cases reported transient metabolic acidosis of undetermined etiology [20,24].

Finally, 3 major syndromes are life threatening: (a) angioedema of the respiratory tract which can lead to their obstruction; (b) significant fluid losses through diarrhea, vomiting and diaphoresis, leading to electrolyte abnormalities, in particular hypokalemia and sometimes metabolic acidosis; and (c) atrioventricular conduction disorders simulating cardiac ischemia.

In humans, severe pain, in addition to the trauma of a prolonged bite, and hypotension result from the physiological effects of horridum toxin, helodermatin and gilatoxin which release bradykinin and angiotensins I and II [28,31–34]. Helodermatin also releases bradykinin, a potent vasodilator that causes a sudden drop in blood pressure, but does not degrade either fibrinogen or plasminogen [32]. The high and abrupt release of bradykinin could explain angioedema, the etiology of which remains unclear, especially since respiratory tract angioedema and vasoplegic shock are generally not associated with other allergic symptoms, especially skin symptoms (pruritus, urticaria, rash, etc.). This suggests non-allergic bradykinin angioedema rather than helodermatid venom anaphylaxis [35], as already suggested [10,29]. However, to our knowledge, immunoglobulins E were never assayed.

Cardiac conduction disturbances with signs of left ventricular ischemia are common in severe Heloderma envenomation. The analogy with takotsubo syndrome is relevant and the atrioventricular conduction disorders show similarities to takotsubo syndrome [10,18,19,22-24], in particular that described in severe scorpion sting envenomation in relation to the sympathetic and then parasympathetic effects due to scorpion venom [36,37]. Usually caused by acute stress, takotsubo syndrome appears to be related to an intense and sudden discharge of catecholamines, which is seen at the onset of the envenomation of the scorpion – and possibly Heloderma as well - which would cause temporary vasoconstriction of the coronary vessels. This hypothesis would explain the transient rise in blood pressure observed in some patients (personal communication, Scott Weinstein) [15], which is common in the onset of takotsubo syndrome.

Hematological abnormalities in blood clotting do not appear to have clinical translation [38]. Helodermatin, a potent proteinase, does not degrade either fibrinogen or plasminogen [39]. However, the decline in fibrinogen observed in few patients [10,23] can be explained by its degradation by gilatoxin [34] and the inhibition of platelet aggregation by phospholipase A_2 [39].

Several peptides belonging to the family of helospectins or helodermins, also called "mimetic incretin", are structural and pharmacological analogues of glucagon and vasoactive intestinal peptide (VIP). They induce a relaxation of smooth muscles and dilation of vessels, especially intestinal vessels, and increases the synthesis of cyclic adenosine monophosphate (cAMP) in enterocytes [8,40,41], enhancing the action of helodermatin and gilatoxin. Profuse diarrhea associated with hypokalemia observed in *Heloderma* bite envenomation suggests a pathological mechanism similar to pancreatic cholera (or Verner-Morrison syndrome) due to a tumor secreting VIP [8]. Helospectin is as effective but less powerful than VIP [8,42] unlike helodermin that is more powerful and has a longer duration of action than VIP [8,43].

An incretin analogue, exendin-4 (exenatide), a 39 amino acid peptide, rises pancreas β -cells proliferation and survival increasing insulin secretion, reduces glucagon secretion, slows down gastric emptying and decreases appetite, which contributes to an anti-diabetic effect [44]. Synthetic exenatide has been marketed since 2005 under the name Byetta[®] for the treatment of type 2 diabetes. It is noteworthy that reported side effects are similar to some symptoms of *Heloderma* envenomation such as nausea, diarrhea, vomiting, abdominal pain, dizziness, cardiac arrhythmia and angioedema. However, amazingly, hypoglycemia has never been reported after *Heloderma* envenomation.

The initial response in first aid is to detach the animal, that often is very difficult because of the tenacious grip commonly exerted when these lizards bite. The use of force,

| lable I. Comparison of do | ocumented n | elodermatid bite er | ivenomations | Dased on the lit | erature. | | | | | | | |
|---------------------------------------|-------------|---------------------|--------------|------------------|---------------|----------------------|---|-----------------------|-------------|------------------|--------------------------------|-----------------|
| References Symptoms | [2] | [10] | [13] | [14] | [15] | _ | [16] | [17] | [18,19] | [20] | [21] | [22] |
| Species | H. s. | H. s. cinctum | H. s. | H. s. | H. s. | H. s. | Н. Һ. | H. s. | Н. s. | Н. s. | Н. s. | Н. s. |
| Size (mm) | 400 | 400 | 473 | 380 | 455 | 455 | 635 | 450 | | | | |
| Bite circumstances | Handling | Handling | Handling | Cage cleaning | Playing | Carriage in a had | Handling | Handling | Handling | Carriage | Capture | Handling |
| Bite duration (seconds) | | 450 | < 300 | 300 | 7 | 5 | 120 | 300 | 15 | | | |
| Gender | Female | Male | Male | Male | Male | Male | Male | Male | Male | Female | Male | Male |
| Age (years) | 50 | 39 | 50 | | 29 | 32 | 39 | 27 | 20 | 29 | 40 | 25 |
| Bite site | Finger | Forearm | Finger | Finger | Finger | Finger | Finger | Finger | Hand | Abdomen | Forearm | Hand |
| Pain | Yes | Yes | Yes | Intense | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Pain diffusion | Yes | Yes | | Yes | | | Yes | Yes | | | | |
| Dizziness | Yes | Yes | Yes | | | | | Yes | | Yes | | |
| Anxiety | | | Yes | | | | | Yes | | | Yes | |
| Diaphoresis | Yes | Yes | Yes | | | | | | | Yes | Yes | Yes |
| Diarrhea | Yes | Yes | | | | | | | | Yes | | |
| Limb edema | | Yes | Yes | Yes | Yes | | | | | | Yes | Yes |
| Dyspnea | | Yes | | | Yes | | | | | | Yes | |
| Agitation | | Yes | | Yes | | | | Yes | | | | |
| Angioedema | | Yes | | | | | | | | Yes | Yes | |
| Admission time (minutes) | | 40 | 06 | 30 | 30 | | 30 | 40 | | 20 | 60 | 10 |
| Nausea | | Yes | | | | Yes | Yes | Yes | | | | Yes |
| Vomiting | | Yes | | | | | Yes | | | Yes | | Yes |
| Cardiac frequency | | 118> 180 | 88 | | 60 | | 120 | 00 | 70 | 150 | 80 | 0> 110 |
| Blood Dressing (mm Ha) | | 56/A5_ 106/65 | 147/80 | | 100/00 | | 127/86 | 00/60 | 135/70 | 01/38 ~ */23 | 100/40 | 0 06/48 |
| Hour Flessure (IIIIII 119) | | Atrial fibrilation | 00/741 | | | | | | | CHIND / 170 | 04/001 | 04/06 / 0 |
| | | | | | | | | | Anomaliar | | Icmiol | CT Anomaliar |
| Electrocarglogram | | ISCNETIA Do | | | | | | | Anomalies | | NOTIMAL | ol Anomalies |
| UXymetry (%) | | 76 000 | 0010 | | 1 1 200 | | l a a a a a a a a a a a a a a a a a a a | | 000 1 | 000 1 1 000 0 | 7000 | 001 |
| | | 20,000 | 8,100 | | 11,/00 | | Normal | | 16.4 | 8,2UU / 24,8UU | 000,62 | 00//c |
| nemographi (g/ ur) plaad statatata | | 201 / 7.CI | | | | | NOTITIAL | | 10.4 | | | 14.0 |
| blood platelets | | 242,000 / 91,000 | | | | | INUTINAL | | | 000,cc1 /000,402 | | |
| FIDRINOGEN (g/L) DT* DTT* | | 1.0 ==> 0.0 | | | | | | | Normal | Diological DTT | Normal | |
| FILT FILT | | | | | | | | | INUITIN | riololigeu ril | INUTINAL | NUTITIAL |
| Fibrin Split Prod. (µg/mL) | | ; | | | | | | | - | | | : |
| Proteinuria Lomatiuria | | Yes | | | | | | | Normal | | | Normal |
| | | | | | | | | | | | | |
| Serum creatinine (mg/L) | | Normal | | | | | | | Normal | | Normai | Normal |
| | | NUTINAL | | | | | | | INUITIN | | | NUTTIAL |
| mypokalenia Metaholic acidosis | | 165 | | | | | | | | Yec Vec | 8 | |
| First improvement (hours) | - | VC | 00 | | | | | | | 17 | ø | |
| Overall regression (hours) | - ~ | 74 26 | 07 | | | | 74 | | | 36 | ہ 15 | |
| Pain relief (hours) | - ۲ | 2 64 | P | 17 | 24 | 6 | 2.5 | | Ranid | 2 | 2 | |
| Treatment | - | Adranalina | Antihintice | Mornhine | Adranalina | 4 | Analoscics III | | Antihintics | Domemine | Adranalina | Adranalina |
| וובמתוובוור | | aloctrical | | antibiotics | mornhino. | | Ananyesics III, corticoctoroide | Cathornau | | antiamotic, | antibictamino | corticostoroids |
| | | cardioversion | | | analgesics II | | | analmesics II | | מוותבווובתר | corticosteroids O ₂ | antihistamine |
| | | analgesics I/III | | | antibiotics | | | antihistamine. | | | | analgesics III |
| | | antibiotics | | | | | | edrophonium, | | | | E |
| | | | | | | | | antibiotics, | | | | |
| Hachital time (dave) | C | 85 85 | ן ה נ | 0.5 | | | 18 | iocal anestnesia 3 | - | ſ | - | ç |
| Recovery (days) | 7 | 60 | <u>6</u> | 2 | 7 | 7 | 2 | ~ ~ | - | 'n | 2 | 1 |
| | | | | | | | | | | | | |

CLINICAL TOXICOLOGY 🍚 3

| References Symptoms | [23–24] | | | 25] | | [26] | [27] | [28] | [29] | [30] |
|-----------------------------------|--------------------------|---------------------|--|-------------------------|-------------------------------|----------------|--|----------------------------------|----------|----------------------------|
| Species Size (mm) | H. s. cinctum | H. s. | Н. s. | H. s. | H. s. | Н. s. 500 | Ч'Н | H. charlesbogerti 470 | H. s. | H. s. 300 |
| Bite circumstances | Handling | Handling | Handling | Handling | Carriage in a bag | Handling | Handling | Handling | Handling | Handling |
| bite autation (seconds) Gender | Male | Male | م Male | Male | < 3 Male | ے Male | Male | Male | Male | Male |
| Age (years) | 23 | 20 | 51 | 29 | 23 | 37 | 40 | 24 | 29 | 41 |
| Bite site | Forearm | Calf | Finger | Finger | Upper arm | Finger | Hand | Hand | Forearm | Finger |
| Pain diffusion | res | res | Yes | Yes | res | Yes | res | Y es Y es | res | res |
| Dizziness | Yes | Yes | | | Yes | Yes | Yes | Yes | | |
| Anxiety | | | Yes | Yes | Yes | | | | | |
| Diaphoresis Diarrhea | Yes | | Yes | | Yes | Yes | Yes | Yes | Yes | |
| Limb edema | Yes | | | | | | Yes | Yes | Yes | |
| Dyspnea Acitation | | Yes | | | | | | Yes | | |
| Angioedema | | | | | | | Yes | Tongue | Mild | |
| Admission time (minutes) | 120 | 45 Voc | 40 | 202 | 120 Voc | 80 Voc | | 15 | Vor | 120 |
| Vomiting | Үес | Yes | | Yes | 5 | 5 | Yes | Yes | Yes | |
| Cardiac frequency | 140 | 140 | 06 | 150 | | 06 | 60 | 102 | 3 | 60 |
| Blood Pressure (mm Hg) | 76/54 | 108/60 | 90/60 - 156/96 | 60/* - 68/* | | 120/60 | 110/63 | 70/52 | | 126/82 |
| Heartbeat | Irregular PVCs | | | | | | | Irregular PVCs | | |
| Electrocardiogram | lschemia | Sinusal | Normal | | | | L | ç | | |
| UXymetry (%) White Blood Cells | 48,300 | 21,500 | | 11,400 | | Normal | دد 18,500 | 99 12,600 | 13,900/ | Normal |
| | | | | | | | | | 27,300 | |
| Hemoglobin (g/dL) | 18.6 | 19.4 | | | | Normal | | | | Normal |
| Blood platelets | 1/1/000 ==> 52,000 | Normal | 0 0 | | | | | | | Normal |
| PT*, PTT* | U.00 Flevated PT, PTT | Normal | o.c Normal | Normal | | Normal | | Normal | | Normal |
| Fibrin Split Prod. (µg/mL) | > 40 | | Normal | | | Normal | | | | |
| Proteinuria | | | | | | | | | | |
| Serum creatinine (md/L) | 30 | | | | | Normal | | | | Normal |
| CPK* (IU) | 4,697 | | | | | 2 | | | | Normal |
| Hypokalemia | Yes | | | | | | | | | |
| Metabolic acidosis | Yes | | | | | | | | | |
| First improvement (hours) | 72 | 14 | 4 | 8 | ; | ! | | 0.5 | | 12 |
| Overall regression (hours) | 16 | 36 | | | 36 | 12 | ∞ α | ω (| | 12 |
| Pain relier (nours) | /2 Floatualiston FFD | 30 Antihistomine | And and and all all all all all all all all all al | Antihistonian | Assolution II | 90 Marahian | 8 Amalancian 11/11 | 12 Amalanaisa I | | 12 20tibioti <i>c</i> o |
| וובמווובוור | Adrenaline, | antibiotics | antibiotics | Anumstamme, naloxone | Analgesics II, antibiotics | antibiotics | antihistamine, | Ariargesics 1, antihistamine, | | diffusion |
| | lidocaine IV | | | | | | corticosteroids, antiemetic | corticosteroids, antiemetic, | | |
| Hospital time (days) | 5 | ĸ | ~ | 0.3 | | 15 | . | anubucs 1 | | 0.75 |
| Recovery (days) | | | < 7 | 1 | < 2 | | | 15 | | 5 |

4 🕳 J.-P. CHIPPAUX AND K. AMRI

shaking the animal, spreading its jaws using a lever, driving a straw into its nostrils or sprinkling it with various liquids (alcohol, chloroform or petrol) are ineffective, time wasting, increase jaw pressure, and may injure the *Heloderma*, including breaking teeth in the wound [17,21,25]. It is possible to quickly pass a flame under the animal's neck or to immerse it in cold water, sometimes resulting in detachment within a few seconds [9,22,25,27]. In some cases, the *Heloderma* promptly and spontaneously detached, especially when placed on a firm supportive surface [11,15,18,25,26,30].

There is no antivenom against *Heloderma* venom. Russell [45] mentioned the existence of two experimental antivenoms manufactured by Arizona State University and the University of Southern California Medical Center for research purpose. However, they have never been further developed or marketed.

Treatment is purely symptomatic and supportive. The choice of analgesics will depend on the intensity of the pain. Analgesic doses of ketamine (intravenous bolus of 0.1–0.5 mg·kg⁻¹ followed by an infusion of 1–2 μ g·kg⁻¹ per minute) may be helpful [46,47]. Wound care includes cleansing and a search for Heloderma teeth fragments [20,22,24,25,28,30]. Elevation of the bitten limb should relieve local edema. Shock may require fluid resuscitation with vasopressor amines (dopamine, adrenaline) if indicated, and electrolyte correction as needed. Cardiac conduction disorders caused by Heloderma envenoming normalize spontaneously with the treatment of shock and hypokalemia. More severe cases may require multiple treatments, as in the case we described (electrical cardioversion, low molecular weight heparin, β -blocker, inhibitor of converting enzyme and antiplatelet agent) [10].

Half of the patients (12 of 21) received a single (9 cases) or 2 antibiotics (3 cases). The indication was not specified but it seems that in most cases it was prophylactic. The significant trauma of the bite and the presence of numerous bacteria in the oral cavity of reptiles raise concerns about wound infection. However, there is a consensus to avoid the prophylactic administration of antibiotics in the event of a reptile bite because, (i) secondary infection is infrequent, (ii) prophylaxis seems ineffective, (iii) the benefit/risk ratio (in particular side effects and resistance) is unfavorable to antibiotics and (iv) it is preferable to choose them on the basis of the germ identification when local signs and the onset of fever suggest a secondary infection [48–50].

Conclusion

Heloderma sp. are quite rare, except in some areas, and mainly nocturnal or diurnal in spring and fall. They live in a restricted geographical area. This limits contact with humans and the risk of bites, apart from herpetologists or amateur collectors who handle them. Generally, the bite induces intense, radiating pain, associated with regional edema with variable severity, significant local wounds, and systemic disorders that are mild in most cases: dizziness, diaphoresis, nausea, vomiting, diarrhea. However, envenomation can be severe, especially after a deep and prolonged bite that promotes the penetration of a large amount of venom. Angioedema, including vasoplegic shock, may be cause for concern and require prompt intervention. Hypovolemia can be severe, sometimes associated with hypokalemia and metabolic acidosis, requiring emergency resuscitation. Finally, cardiac disorders (arrhythmia and ventricular ischemia), appear to be transient, but can be life threatening.

In the absence of antivenom, treatment is only symptomatic and supportive, sometimes requiring intensive care for respiratory support, treatment of cardiac abnormalities and restoration of electrolyte disorders.

Acknowledgements

The authors thank Leslie Boyer, Steven Seifert and Scott Weinstein for their skilled advices, help in providing with relevant papers. They are particularly grateful to Scott Weinstein for his careful review of the manuscript, and his relevant and useful suggestions.

Disclosure statement

No potential conflict of interest was reported by the author(s).

ORCID

Jean-Philippe Chippaux (b) http://orcid.org/0000-0002-1976-8568

References

- Bogert CRD, Campo RD. The Gila monster and its allies. Bull Am Mus Nat Hist. 1956;109:1–238.
- [2] Reiserer RS, Schuett GWS, Beck D. Taxonomic reassessment and conservation status of the beaded lizard, *Heloderma horridum* (Squamata: Helodermatidae). Amphib Reptile Conserv. 2013;7(1): 74–96.
- [3] Phisalix M. Effet de la morsure d'un lézard venimeux d'Arizona, l'Heloderma suspectum Cope. C R Acad Sci. 1911;152:1790–1792.
- [4] Weinstein SA, Smith TL, Kardong KV. Reptile venom glands form, function, and future. In Mackessy SP, editor. Handbook of venoms and toxins of reptiles. Boca Raton: Taylor & Francis, CRC Press; 2009. p. 76–84.
- [5] Koludarov I, Jackson TN, Sunagar K, et al. Fossilized venom: the unusually conserved venom profiles of *Heloderma* species (beaded lizards and Gila monsters). Toxins. 2014;6(12):3582–3595.
- [6] Sanggaard KW, Dyrlund TF, Thomsen LR, et al. Characterization of the Gila monster (*Heloderma suspectum suspectum*) venom proteome. J Proteomics. 2015;117:1–11.
- [7] Russell FE, Bogert CM. Gila monster: its biology, venom and bite—a review. Toxicon. 1981;19(3):341–359.
- [8] Raufman JP. Bioactive peptides from lizard venoms. Regul Pept. 1996;61(1):1–18.
- [9] Miller MF. Gila monster envenomation. Ann Emerg Med. 1995; 25(5):720.
- [10] Amri K, Chippaux JP. Report of a severe *Heloderma suspectum* envenomation. Clin Toxicol. 2020;:1–4. DOI: 10.1080/15563650. 2020.1804574.
- [11] French R, Brooks D, Ruha AM, et al. Gila monster (*Heloderma suspectum*) envenomation: Descriptive analysis of calls to United States Poison Centers with focus on Arizona cases. Clin Toxicol. 2015;53(1):60–70.
- [12] Woodson WD. Toxicity of *Heloderma* venom. Herpetologica. 1947; 1:31–33.

- [13] Grant ML, Henderson LJ. A case of Gila monster poisoning with a summary of some previous accounts. Proc Iowa Acad Sci. 1957; 64:686–697.
- [14] Duellman WE. A case of *Heloderma* poisoning. Copeia. 1950; 1950(2):151.
- [15] Shannon FA. Case reports of two Gila monster bites. Herpetologica. 1953;9(3):125–127.
- [16] Albritton DC, Parrish HM, Allen ER. Venenation by the Mexican beaded lizard (*Heloderma horridum*): report of a case. S Dakota J Med. 1970;23(4):9–11.
- [17] Stahnke HL, Heffron WA, Lewis DL. Bite of the Gila monster. Rocky Mtn Med J. 1970;67:25–30.
- [18] Roller JA. Gila monster bite: a case report. Clin Toxicol. 1977; 10(4):423–427.
- [19] Roller JA, Davis DH. Letter: Gila monster bite. JAMA. 1976;235(3): 249–250.
- [20] Heitschel S. Near death from a Gila monster bite. J Emerg Nurs. 1986;12(5):259–262.
- [21] Piacentine J, Curry SC, Ryan PJ. Life-threatening anaphylaxis following Gila monster bite. Ann Emerg Med. 1986;15(8):959–961.
- [22] Streiffer RH. Bite of the venomous lizard, the Gila monster. Postgrad Med. 1986;79(2):297–302.
- [23] Bou-Abboud CF, Kardassakis DG. Acute myocardial infarction following a Gila monster (*Heloderma suspectum*) bite. West J Med. 1988;148(5):577–579.
- [24] Preston CA. Hypotension, myocardial infarction, and coagulopathy following Gila monster bite. J Emerg Med. 1989;7(1):37–40.
- [25] Hooker KR, Caravati EM, Hartsell SC. Gila monster envenomation [published correction appears in Ann Emerg Med 1995 Jan;25(1):47]. Ann Emerg Med. 1994;24(4):731–735.
- [26] Strimple PD, Tomassoni AJ, Otten EJ, et al. Report on envenomation by a Gila monster *Heloderma suspectum* with a discussion of venom apparatus, clinical findings, and treatment. Wilderness Environ Med. 1997;8(2):111–116.2.3.CO;2]
- [27] Cantrell FL. Envenomation by the Mexican beaded lizard: a case report. J Toxicol Clin Toxicol. 2003;41(3):241–244.
- [28] Ariano-Sánchez D. Envenomation by a wild Guatemalan Beaded Lizard *Heloderma horridum charlesbogerti*. Clin Toxicol. 2008;46(9): 897–899.
- [29] French RN, Ash J, Brooks DE. Gila monster bite. Clin Toxicol. 2012;50(2):151–152.
- [30] Wong OF, Cheung WH, Fung HT, et al. A case of Gila monster (*Heloderma suspectum*) bite. Hong Kong J Emerg Med. 2018;25(6): 362–365.
- [31] Hendon RA, Tu AT. Biochemical characterization of the lizard toxin gilatoxin. Biochemistry. 1981;20(12):3517–3522.
- [32] Alagón A, Possani LD, Smart J, et al. Helodermatine, a kallikreinlike, hypotensive enzyme from the venom of *Heloderma horridum horridum* (Mexican beaded lizard). J Exp Med. 1986;164(6): 1835–1845.
- [33] Nikai T, Imai K, Sugihara H, et al. Isolation and characterization of horridum toxin with arginine ester hydrolase activity from

Heloderma horridum (beaded lizard) venom. Arch Biochem Biophys. 1988;264(1):270–280.

- [34] Utaisincharoen P, Mackessy SP, Miller RA, et al. Complete primary structure and biochemical properties of gilatoxin, a serine protease with kallikrein-like and angiotensin-degrading activities. J Biol Chem. 1993;268(29):21975–21983.,
- [35] Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy. 2007;62(8):842–856.
- [36] Abroug F, Souheil E, Ouanes I, et al. Ouanes Besbes L. Scorpionrelated cardiomyopathy: clinical characteristics, pathophysiology, and treatment. Clin Toxicol. 2015;53(6):511–518.
- [37] Madias JE. Scorpion envenomation cardiomyopathy: a promising model for takotsubo syndrome. Clin Toxicol. 2015;53(7):787
- [38] Patterson RA, Lee IS. Effects of *Heloderma suspectum* venom on blood coagulation. Toxicon. 1969;7(4):321–324.
- [39] Huang TF, Chiang HS. Effect on human platelet aggregation of phospholipase A2 purified from *Heloderma horridum* (beaded lizard) venom. Biochim Biophys Acta. 1994;1211(1):61–68.
- [40] Uddman R, Goadsby PJ, Jansen-Olesen I, et al. Helospectin-like peptides: immunochemical localization and effects on isolated cerebral arteries and on local cerebral blood flow in the cat. J Cereb Blood Flow Metab. 1999;19(1):61–67.
- [41] Cardell M, Cardell LO. Helospectin, induces a potent relaxation of human airways in vitro. Peptides. 2001;22(9):1359–1362.
- [42] Parker DS, Raufman JP, O'Donohue TL, et al. Amino acid sequences of helospectins, new members of the glucagon superfamily, found in Gila monster venom. J Biol Chem. 1984;259(19): 11751–11755.,
- [43] Naruse S, Yasui A, Kishida S, et al. Helodermin has a VIP-like effect upon canine blood flow. Peptides. 1986;7(Suppl1):237–240.
- [44] Furman BL. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon. 2012;59(4):464–471.
- [45] Russell FE. Snake venom poisoning. JB Lippincott Co, Philadelphia. 1980. 395–419.
- [46] Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci. 1982;71(5):539–542.
- [47] Brandehoff N, Benjamin JM, Balde C, et al. Ketamine for pain control of snake envenomation in Guinea: a case series. Toxicon. 2020;187:82–85.
- [48] LoVecchio F, Klemens J, Welch S, et al. Antibiotics after rattlesnake envenomation. J Emerg Med. 2002;23(4):327–328.
- [49] Terry P, Mackway-Jones K. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. The use of antibiotics in venomous snake bite. Emerg Med J. 2002; 19(1):48–49.
- [50] Sachett JAG, da Silva IM, Alves EC, et al. Poor efficacy of preemptive amoxicillin clavulanate for preventing secondary infection from Bothrops snakebites in the Brazilian Amazon: a randomized controlled clinical trial. PLOS Negl Trop Dis. 2017;11(7):e0005745.